TY - JOUR
T1 - Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma
T2 - A Multi-Institutional Study in Japan
AU - Ito, Keiichi
AU - Mikami, Shuji
AU - Tatsugami, Katsunori
AU - Masumori, Naoya
AU - Shinohara, Nobuo
AU - Kondo, Tsunenori
AU - Nakanishi, Shotaro
AU - Nagashima, Yoji
AU - Eto, Masatoshi
AU - Kamba, Tomomi
AU - Kuroda, Naoto
AU - Tomita, Yoshihiko
AU - Matsuyama, Hideyasu
AU - Onishi, Tetsuro
AU - Tsushima, Tomoyasu
AU - Nakazawa, Hayakazu
AU - Oya, Mototsugu
AU - Ozono, Seiichiro
AU - Naito, Seiji
AU - Asano, Tomohiko
N1 - Funding Information:
The authors would like to thank all members of the Collaboration Study of the Japanese Society of Renal Cancer. Other collaborators of the Collaboration Study of the Japanese Society of Renal Cancer participated in this study: Megumi Hirobe, Sapporo Medical University School of Medicine, Sapporo, Japan; Sachiyo Murai, Hokkaido University Graduate School of Medicine, Sapporo, Japan; Toshio Takagi, Tokyo Women's Medical University, Tokyo, Japan; Seiichi Saito, University of the Ryukyus Graduate School of Medicine, Okinawa, Japan; Noboru Shibasaki and Toshinari Yamasaki, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Takanobu Motoshima, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; Tomohiro Shibasaki, Yamagata University Faculty of Medicine, Yamagata, Japan; Yoshihisa Kawai and Kazuhiro Nagao, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan; Masahiro Yamashita, NHO Okayama Medical Center, Okayama, Japan; Fumio Ito, Tokyo Women's Medical University Medical Center East, Tokyo, Japan; and Ryuichi Mizuno, Keio University School of Medicine, Tokyo, Japan. This work was supported in part by Grants-in-Aid for Scientific Research (#16K08657 to S.M., #17K11162 to Y.N.) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
Funding Information:
The authors would like to thank all members of the Collaboration Study of the Japanese Society of Renal Cancer. Other collaborators of the Collaboration Study of the Japanese Society of Renal Cancer participated in this study: Megumi Hirobe, Sapporo Medical University School of Medicine, Sapporo, Japan; Sachiyo Murai, Hokkaido University Graduate School of Medicine, Sapporo, Japan; Toshio Takagi, Tokyo Women’s Medical University, Tokyo, Japan; Seiichi Saito, University of the Ryukyus Graduate School of Medicine, Okinawa, Japan; Noboru Shibasaki and Toshinari Yamasaki, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Takanobu Motoshima, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; Tomohiro Shibasaki, Yamagata University Faculty of Medicine, Yamagata, Japan; Yoshihisa Kawai and Kazuhiro Nagao, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan; Masahiro Yamashita, NHO Okayama Medical Center, Okayama, Japan; Fumio Ito, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan; and Ryuichi Mizuno, Keio University School of Medicine, Tokyo, Japan. This work was supported in part by Grants-in-Aid for Scientific Research (#16K08657 to S.M., #17K11162 to Y.N.) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan .
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/12
Y1 - 2018/12
N2 - Background: Standard treatments have not been established in metastatic papillary renal-cell carcinoma (PRCC). We aimed to investigate treatment outcomes in patients with mPRCC. Patients and Methods: This study included 51 patients who were diagnosed with PRCC at 14 institutions. Pathologic slides were reviewed by pathologists. The associations between clinical factors and overall survival (OS) were analyzed. Results: Final pathologic diagnoses could be determined in 50 patients. Thirty-five tumors were diagnosed as PRCC (type 2 PRCC, 91.4%), and 15 were diagnosed as other histologic types. Targeted therapies (TTs) were provided to 25 mPRCC patients. Patients treated with TT survived significantly longer than those treated before the era of TT (median OS, 22.5 vs. 6.3 months; P = .0035). Median OS of patients who experienced stable disease for ≥ 9 months using single TT was 43.1 months. Patients treated with a tyrosine kinase inhibitor (TKI) as first-line TT survived longer after TT initiation than those treated with an mTOR inhibitor (median, 22.4 vs. 11.7 months; P = .2684). Patients treated with TKIs in both first- and second-line settings had significantly better survival after TT initiation than those treated with a TKI in one therapy line and an mTOR inhibitor in the other (31.4 vs. 12.9 months, P = .0172). Patients treated with a TKI as second-line TT survived significantly longer after second-line TT initiation than did those treated with an mTOR inhibitor (16.2 vs. 7.4 months, P = .0016). Conclusion: Prognoses of patients with mPRCC were improved by TT, and TKIs appeared to be the treatment of choice in both the first- and second-line settings. We aimed to investigate treatment outcomes in patients with metastatic papillary renal-cell carcinoma. Patients treated with targeted therapy (TT) survived significantly longer than those treated before the era of TT. Patients treated with tyrosine kinase inhibitors (TKIs) in both first- and second-line settings had significantly better survival after initiation of TT than those treated with a TKI in one therapy line and an mTOR inhibitor in the other.
AB - Background: Standard treatments have not been established in metastatic papillary renal-cell carcinoma (PRCC). We aimed to investigate treatment outcomes in patients with mPRCC. Patients and Methods: This study included 51 patients who were diagnosed with PRCC at 14 institutions. Pathologic slides were reviewed by pathologists. The associations between clinical factors and overall survival (OS) were analyzed. Results: Final pathologic diagnoses could be determined in 50 patients. Thirty-five tumors were diagnosed as PRCC (type 2 PRCC, 91.4%), and 15 were diagnosed as other histologic types. Targeted therapies (TTs) were provided to 25 mPRCC patients. Patients treated with TT survived significantly longer than those treated before the era of TT (median OS, 22.5 vs. 6.3 months; P = .0035). Median OS of patients who experienced stable disease for ≥ 9 months using single TT was 43.1 months. Patients treated with a tyrosine kinase inhibitor (TKI) as first-line TT survived longer after TT initiation than those treated with an mTOR inhibitor (median, 22.4 vs. 11.7 months; P = .2684). Patients treated with TKIs in both first- and second-line settings had significantly better survival after TT initiation than those treated with a TKI in one therapy line and an mTOR inhibitor in the other (31.4 vs. 12.9 months, P = .0172). Patients treated with a TKI as second-line TT survived significantly longer after second-line TT initiation than did those treated with an mTOR inhibitor (16.2 vs. 7.4 months, P = .0016). Conclusion: Prognoses of patients with mPRCC were improved by TT, and TKIs appeared to be the treatment of choice in both the first- and second-line settings. We aimed to investigate treatment outcomes in patients with metastatic papillary renal-cell carcinoma. Patients treated with targeted therapy (TT) survived significantly longer than those treated before the era of TT. Patients treated with tyrosine kinase inhibitors (TKIs) in both first- and second-line settings had significantly better survival after initiation of TT than those treated with a TKI in one therapy line and an mTOR inhibitor in the other.
KW - Central pathologic review
KW - Prognosis
KW - Targeted therapy
KW - Tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85053222708&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053222708&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2018.07.028
DO - 10.1016/j.clgc.2018.07.028
M3 - Article
C2 - 30224330
AN - SCOPUS:85053222708
SN - 1558-7673
VL - 16
SP - e1201-e1214
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 6
ER -